These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1148 related items for PubMed ID: 29520964

  • 1. Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology.
    Seferović PM, Petrie MC, Filippatos GS, Anker SD, Rosano G, Bauersachs J, Paulus WJ, Komajda M, Cosentino F, de Boer RA, Farmakis D, Doehner W, Lambrinou E, Lopatin Y, Piepoli MF, Theodorakis MJ, Wiggers H, Lekakis J, Mebazaa A, Mamas MA, Tschöpe C, Hoes AW, Seferović JP, Logue J, McDonagh T, Riley JP, Milinković I, Polovina M, van Veldhuisen DJ, Lainscak M, Maggioni AP, Ruschitzka F, McMurray JJV.
    Eur J Heart Fail; 2018 May; 20(5):853-872. PubMed ID: 29520964
    [Abstract] [Full Text] [Related]

  • 2. European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure.
    Seferović PM, Coats AJS, Ponikowski P, Filippatos G, Huelsmann M, Jhund PS, Polovina MM, Komajda M, Seferović J, Sari I, Cosentino F, Ambrosio G, Metra M, Piepoli M, Chioncel O, Lund LH, Thum T, De Boer RA, Mullens W, Lopatin Y, Volterrani M, Hill L, Bauersachs J, Lyon A, Petrie MC, Anker S, Rosano GMC.
    Eur J Heart Fail; 2020 Feb; 22(2):196-213. PubMed ID: 31816162
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. The influence of anti-hyperglycemic drug therapy on cardiovascular and heart failure outcomes in patients with type 2 diabetes mellitus.
    Asleh R, Sheikh-Ahmad M, Briasoulis A, Kushwaha SS.
    Heart Fail Rev; 2018 May; 23(3):445-459. PubMed ID: 29270818
    [Abstract] [Full Text] [Related]

  • 6. Cardiovascular effects of non-insulin glucose-lowering agents: a comprehensive review of trial evidence and potential cardioprotective mechanisms.
    Savarese G, Butler J, Lund LH, Bhatt DL, Anker SD.
    Cardiovasc Res; 2022 Jul 27; 118(10):2231-2252. PubMed ID: 34390570
    [Abstract] [Full Text] [Related]

  • 7. The heart failure burden of type 2 diabetes mellitus-a review of pathophysiology and interventions.
    Ofstad AP, Atar D, Gullestad L, Langslet G, Johansen OE.
    Heart Fail Rev; 2018 May 27; 23(3):303-323. PubMed ID: 29516230
    [Abstract] [Full Text] [Related]

  • 8. Sodium-glucose co-transporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology.
    Seferović PM, Fragasso G, Petrie M, Mullens W, Ferrari R, Thum T, Bauersachs J, Anker SD, Ray R, Çavuşoğlu Y, Polovina M, Metra M, Ambrosio G, Prasad K, Seferović J, Jhund PS, Dattilo G, Čelutkiene J, Piepoli M, Moura B, Chioncel O, Ben Gal T, Heymans S, de Boer RA, Jaarsma T, Hill L, Lopatin Y, Lyon AR, Ponikowski P, Lainščak M, Jankowska E, Mueller C, Cosentino F, Lund L, Filippatos GS, Ruschitzka F, Coats AJS, Rosano GMC.
    Eur J Heart Fail; 2020 Sep 27; 22(9):1495-1503. PubMed ID: 32618086
    [Abstract] [Full Text] [Related]

  • 9. Heart failure outcomes in clinical trials of glucose-lowering agents in patients with diabetes.
    Fitchett DH, Udell JA, Inzucchi SE.
    Eur J Heart Fail; 2017 Jan 27; 19(1):43-53. PubMed ID: 27653447
    [Abstract] [Full Text] [Related]

  • 10. Clinical potential relevance of metabolic properties of SGLT2 inhibitors in patients with heart failure.
    Galli M, D'Amario D, Sofia C, Vaccarella M, Crea F, Aspromonte N.
    Expert Opin Drug Metab Toxicol; 2018 Dec 27; 14(12):1273-1285. PubMed ID: 30472914
    [Abstract] [Full Text] [Related]

  • 11. Glucagon-Like Peptide 1 Receptor Agonists and Heart Failure: The Need for Further Evidence Generation and Practice Guidelines Optimization.
    Khan MS, Fonarow GC, McGuire DK, Hernandez AF, Vaduganathan M, Rosenstock J, Handelsman Y, Verma S, Anker SD, McMurray JJV, Kosiborod MN, Butler J.
    Circulation; 2020 Sep 22; 142(12):1205-1218. PubMed ID: 32955939
    [Abstract] [Full Text] [Related]

  • 12. Heart Failure With Type 2 Diabetes Mellitus: Association Between Antihyperglycemic Agents, Glycemic Control, and Ejection Fraction.
    Lin SN, Phang KK, Toh SH, Chee KH, Zaman Huri H.
    Front Endocrinol (Lausanne); 2020 Sep 22; 11():448. PubMed ID: 32754118
    [Abstract] [Full Text] [Related]

  • 13. Physiological monitoring of the complex multimorbid heart failure patient - diabetes and monitoring glucose control.
    Seferović PM, Jhund PS.
    Eur Heart J Suppl; 2019 Dec 22; 21(Suppl M):M20-M24. PubMed ID: 31908611
    [Abstract] [Full Text] [Related]

  • 14. Heart Failure Association of the European Society of Cardiology update on sodium-glucose co-transporter 2 inhibitors in heart failure.
    Seferović PM, Fragasso G, Petrie M, Mullens W, Ferrari R, Thum T, Bauersachs J, Anker SD, Ray R, Çavuşoğlu Y, Polovina M, Metra M, Ambrosio G, Prasad K, Seferović J, Jhund PS, Dattilo G, Čelutkiene J, Piepoli M, Moura B, Chioncel O, Ben Gal T, Heymans S, Jaarsma T, Hill L, Lopatin Y, Lyon AR, Ponikowski P, Lainščak M, Jankowska E, Mueller C, Cosentino F, Lund LH, Filippatos GS, Ruschitzka F, Coats AJS, Rosano GMC.
    Eur J Heart Fail; 2020 Nov 22; 22(11):1984-1986. PubMed ID: 33068051
    [Abstract] [Full Text] [Related]

  • 15. Cardiovascular benefits and safety of non-insulin medications used in the treatment of type 2 diabetes mellitus.
    Yandrapalli S, Jolly G, Horblitt A, Sanaani A, Aronow WS.
    Postgrad Med; 2017 Nov 22; 129(8):811-821. PubMed ID: 28749197
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Use of sodium-glucose co-transporter 2 inhibitors in patients with heart failure and type 2 diabetes mellitus: data from the Swedish Heart Failure Registry.
    Becher PM, Schrage B, Ferrannini G, Benson L, Butler J, Carrero JJ, Cosentino F, Dahlström U, Mellbin L, Rosano GMC, Sinagra G, Stolfo D, Lund LH, Savarese G.
    Eur J Heart Fail; 2021 Jun 22; 23(6):1012-1022. PubMed ID: 33599357
    [Abstract] [Full Text] [Related]

  • 18. Non-insulin antihyperglycaemic drugs and heart failure: an overview of current evidence from randomized controlled trials.
    Savarese G, Schrage B, Cosentino F, Lund LH, Rosano GMC, Seferovic P, Butler J.
    ESC Heart Fail; 2020 Dec 22; 7(6):3438-3451. PubMed ID: 32909376
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. SGLT2 Inhibitors vs. GLP-1 Agonists to Treat the Heart, the Kidneys and the Brain.
    Rolek B, Haber M, Gajewska M, Rogula S, Pietrasik A, Gąsecka A.
    J Cardiovasc Dev Dis; 2023 Jul 30; 10(8):. PubMed ID: 37623335
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 58.